PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Net Receivables Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x RVPH's -54.11%. Michael Burry might investigate for potential short-term asset misclassification or risk.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero Total Non-Current Assets Growth.
100.00%
Higher Other Assets Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-99.84%
Less than half of RVPH's 5.25%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Above 1.5x RVPH's -49.51%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
100.00%
Exceeding 1.5x RVPH's 8.21%. Michael Burry suspects ballooning short-term obligations vs. competitor.
13.77%
Above 1.5x RVPH's 4.94%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Less than half of RVPH's -40.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
11.40%
Above 1.5x RVPH's 4.83%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.71%
Similar yoy to RVPH's -3.55%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
110.36%
Higher Other Stockholders' Equity Items Growth compared to RVPH's zero value, indicating worse performance.
-11.42%
Below half RVPH's 89.71%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Less than half of RVPH's -49.51%. David Dodd sees less overall debt expansion vs. competitor.
10.35%
Less than half of RVPH's -102.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.